Von Willebrand disease 2
MONDO:0013304Type 2 von Willebrand disease (type 2 VWD) is a form of VWD characterized by a bleeding disorder associated with a qualitative deficiency and functional anomalies of the Willebrand factor (von Willebrand factor; VWF).
Also known as: VWD2, von Willebrand disease 2, von Willebrand disease type 2, von Willebrand disease, types 2A, 2B, 2M, and 2N, von Willebrand's disease type 2, von willebrand's disease 2, VON WILLEBRAND disease, type 2, VWD, type 2
18 clinical trials for this condition and its sub-types, 4 tagged with Von Willebrand disease 2 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Von Willebrand disease 2
-
Von Willebrand disease type 2A 2 trials
-
Von Willebrand disease type 2N 2 trials
-
Von Willebrand disease type 2B 1 trial
-
Von Willebrand disease type 2M 1 trial
-
Battlefield plasma goes civil: can a powder save trauma victims?
Disease control CompletedThis study tested a freeze-dried plasma product that can be mixed with water in 6 minutes, avoiding the long thaw time of standard plasma. It included 42 trauma patients with severe bleeding who needed blood transfusions. The goal was to see if faster plasma delivery could improv…
Phase 3 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New blood product could cut transfusions in major surgeries
Disease control CompletedThis study tested a pathogen-reduced version of cryoprecipitate, a blood product that helps blood clot, in 208 patients undergoing liver transplant or heart surgery. The goal was to see if having this product readily available could stop bleeding early and reduce the need for oth…
Phase 4 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New hope for rare bleeding disorder: BIVV001 tested in humans
Disease control CompletedThis early-stage trial tested a single injection of a new drug called BIVV001 in 6 adults with severe forms of von Willebrand disease (types 2N and 3). The goal was to see how the drug behaves in the body and whether it is safe. If results are promising, larger studies could foll…
Phase 1 • Sponsor: Bioverativ, a Sanofi company • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC